PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-6.85%
Negative revenue growth while AVGO stands at 0.07%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-5.06%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-2.78%
Negative EBIT growth while AVGO is at 32.81%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-2.78%
Negative operating income growth while AVGO is at 32.81%. Joel Greenblatt would press for urgent turnaround measures.
-5.31%
Negative net income growth while AVGO stands at 137.82%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-5.26%
Negative EPS growth while AVGO is at 137.50%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-5.68%
Negative diluted EPS growth while AVGO is at 138.00%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-0.37%
Share reduction while AVGO is at 0.25%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
0.67%
Diluted share reduction more than 1.5x AVGO's 4.28%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
2.02%
Dividend growth under 50% of AVGO's 101.84%. Michael Burry might suspect more pressing needs for cash or weaker earnings power.
-39.53%
Negative OCF growth while AVGO is at 0.07%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-48.79%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
86.02%
10Y revenue/share CAGR under 50% of AVGO's 503.24%. Michael Burry would suspect a lasting competitive disadvantage.
50.25%
5Y revenue/share CAGR under 50% of AVGO's 351.42%. Michael Burry would suspect a significant competitive gap or product weakness.
57.02%
3Y revenue/share CAGR under 50% of AVGO's 264.31%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
495.91%
10Y OCF/share CAGR under 50% of AVGO's 18241.73%. Michael Burry would worry about a persistent underperformance in cash creation.
98.76%
Below 50% of AVGO's 497.69%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
102.08%
3Y OCF/share CAGR under 50% of AVGO's 268.71%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
110.08%
Below 50% of AVGO's 2036.42%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
60.55%
5Y net income/share CAGR above 1.5x AVGO's 17.40%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
189.06%
3Y net income/share CAGR above 1.5x AVGO's 11.31%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
153.51%
Equity/share CAGR of 153.51% while AVGO is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
34.80%
Below 50% of AVGO's 472.89%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
-0.08%
Negative 3Y equity/share growth while AVGO is at 296.98%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
53.94%
Below 50% of AVGO's 333.82%. Michael Burry suspects the firm invests elsewhere or can’t match the competitor’s dividend policy.
3.56%
Our AR growth while AVGO is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
-5.74%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
-3.55%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-5.76%
We have a declining book value while AVGO shows 0.36%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-0.07%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
0.58%
R&D growth drastically higher vs. AVGO's 0.25%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
-1.24%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.